Who is affected by this change?

This affects Independence Blue Cross Endocrinology, Nephrology, Cardiology, Neurology providers on Commercial plans.

When does this change take effect?

This change is effective Mar 4, 2026.

Back to dashboard

CommercialCoverageLow impact

08.00.69d, Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio)

Independence Blue Cross·Endocrinology, Nephrology, Cardiology +1 more·Pharmacy

Effective date

Mar 4, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Policy 08.00.69d for Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio) has been reissued for commercial plans. This policy covers rare disease treatments for Fabry disease and will take effect March 4, 2026.

Action Required

Action needed

By March 4, 2026: Billing team should review the full policy details at the provided URL to understand any changes to coverage criteria for Fabrazyme® and Elfabrio treatments. Monitor for updated prior authorization requirements or documentation needs for these rare disease medications.

Related policy hubs

Independence Blue Cross policies Endocrinology Nephrology Cardiology Neurology